Scopus BioPharma Inc. Common Stock
SCPS
SCPS was delisted on the 16th of December, 2022.
4 hedge funds and large institutions have $639K invested in Scopus BioPharma Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$288K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$266K |
| 3 |
First Manhattan
New York
|
+$184K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$24.3K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $242K | +$288K | +16,280 | New |
|
|
SSA
2
Schonfeld Strategic Advisors
New York
| $223K | +$266K | +15,000 | New |
|
|
3
First Manhattan
New York
| $154K | +$184K | +10,400 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $20K | +$24.3K | +1,370 | New |
|
SCPS Hedge Fund Activity: Q4 2020 in Review
4 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q4 2020, worth a combined $639K.
Buyers outnumbered sellers: 4 funds opened new SCPS positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $288K.
- 4 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $639K of Scopus BioPharma Inc. Common Stock stock for Q4 2020.
- 4 funds opened new Scopus BioPharma Inc. Common Stock positions in Q4 2020 and 0 closed out, a net change of +4 holders.
- The largest Scopus BioPharma Inc. Common Stock buyer in Q4 2020 was Virtu Financial, an estimated $288K added.
Based on aggregated 13F filings for Q4 2020.